e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.41 -0.08 (-0.13%)

Streaming Delayed Price Updated: 3:18 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

44 45 Next >

Why Is Sierra Oncology (SRRA) Stock Up Today? ↗

April 13, 2022

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Via InvestorPlace

Sierra Oncology Stock Is Soaring: Here's Why ↗

April 13, 2022

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in...

Via Benzinga

Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗

April 13, 2022

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Via Investor's Business Daily

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029 ↗

April 11, 2022

Via Benzinga

Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)

April 11, 2022

Via Investor Brand Network

Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)

April 11, 2022

Via Investor Brand Network

Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here ↗

April 06, 2022

Via Benzinga

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal ↗

April 13, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK) ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins ↗

April 11, 2022

The move comes after the FDA shut down its Vir-partnered Covid antibody, however.

Via Investor's Business Daily

What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates? ↗

April 07, 2022

Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.

Via Benzinga

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial ↗

March 30, 2022

Via Benzinga

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact ↗

March 23, 2022

Via Benzinga

New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+

April 06, 2022

From GSK

Via Business Wire

Good and Bad stock news ↗

April 05, 2022

Microsoft is down because of an FTC investigation of its possible anti-competitive moves.

Via Talk Markets

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine ↗

March 30, 2022

Via Benzinga

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility ↗

March 30, 2022

Vir Biotechnology remains under pressure despite its looming addition to a new index.

Via Investor's Business Daily

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ ↗

March 30, 2022

According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging...

Via Benzinga

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV ↗

March 29, 2022

Via Benzinga

Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness ↗

March 29, 2022

President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country

Via Benzinga

Monday Markets News ↗

March 28, 2022

Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.

Via Talk Markets

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant ↗

March 28, 2022

Via Benzinga

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗

March 28, 2022

As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.

Via InvestorPlace

Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗

March 25, 2022

Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,

Via Benzinga

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag ↗

March 24, 2022

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

Via Investor's Business Daily

Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC ↗

March 24, 2022

The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.

Via Benzinga

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market ↗

March 21, 2022

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy